Krystal Biotech Inc (NASDAQ:KRYS)
| 104.01 Delayed Data As of 3:59pm ET |  -0.91 / -0.87%Today’s Change | 69.81 Today|||52-Week Range 132.68 | +31.29% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $3.0B |
Company Description
Krystal Biotech, Inc. is a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases. The company's wide-ranging pipeline is based on its proprietary redosable HSV vector. The firm is led by an experienced management team, is fully-integrated and has core capabilities in viral vector design, vector optimization, gene therapy manufacturing and commercialization. Krystal was founded by Krish Krishnan & Suma M. Krishnan on April 15, 2016 and is headquartered in Pittsburgh, PA.
Contact Information
Krystal Biotech, Inc. 2100 Wharton Street Pittsburgh Pennsylvania 15203 |
Employees
Shareholders
| Mutual fund holders | 44.77% |
| Other institutional | 38.77% |
| Individual stakeholders | 17.83% |
Top Executives
| Krish S. Krishnan | Chairman, President & Chief Executive Officer |
| Suma M. Krishnan | Director, President-Research & Development |
| George Chen | Manager-Information Technology & CSV |
| Trevor Parry | Vice President-Research & Scientific Affairs |
| David Glynn | General Counsel-Commercial & Compliance |
